JP2021519072A5 - - Google Patents

Info

Publication number
JP2021519072A5
JP2021519072A5 JP2020551549A JP2020551549A JP2021519072A5 JP 2021519072 A5 JP2021519072 A5 JP 2021519072A5 JP 2020551549 A JP2020551549 A JP 2020551549A JP 2020551549 A JP2020551549 A JP 2020551549A JP 2021519072 A5 JP2021519072 A5 JP 2021519072A5
Authority
JP
Japan
Prior art keywords
gnc
cancer cells
guidance
binding domain
navigation control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519072A (ja
JP7573441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024105 external-priority patent/WO2019191120A1/en
Publication of JP2021519072A publication Critical patent/JP2021519072A/ja
Publication of JP2021519072A5 publication Critical patent/JP2021519072A5/ja
Priority to JP2024180215A priority Critical patent/JP7781243B2/ja
Application granted granted Critical
Publication of JP7573441B2 publication Critical patent/JP7573441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551549A 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 Active JP7573441B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180215A JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648888P 2018-03-27 2018-03-27
US201862648880P 2018-03-27 2018-03-27
US62/648,888 2018-03-27
US62/648,880 2018-03-27
PCT/US2019/024105 WO2019191120A1 (en) 2018-03-27 2019-03-26 Guidance and navigation control proteins and method of making and using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180215A Division JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Publications (3)

Publication Number Publication Date
JP2021519072A JP2021519072A (ja) 2021-08-10
JP2021519072A5 true JP2021519072A5 (cg-RX-API-DMAC7.html) 2022-05-11
JP7573441B2 JP7573441B2 (ja) 2024-10-25

Family

ID=68060498

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020551503A Pending JP2021519289A (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2020551549A Active JP7573441B2 (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2023216572A Pending JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2024180215A Active JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020551503A Pending JP2021519289A (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023216572A Pending JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2024180215A Active JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Country Status (11)

Country Link
US (2) US12029761B2 (cg-RX-API-DMAC7.html)
EP (2) EP3773621A4 (cg-RX-API-DMAC7.html)
JP (4) JP2021519289A (cg-RX-API-DMAC7.html)
KR (2) KR20200135935A (cg-RX-API-DMAC7.html)
CN (5) CN111527108A (cg-RX-API-DMAC7.html)
AU (4) AU2019243453B2 (cg-RX-API-DMAC7.html)
CA (2) CA3094997A1 (cg-RX-API-DMAC7.html)
IL (4) IL312224B2 (cg-RX-API-DMAC7.html)
SG (2) SG11202008474QA (cg-RX-API-DMAC7.html)
TW (2) TW201945013A (cg-RX-API-DMAC7.html)
WO (2) WO2019191125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11787863B2 (en) * 2017-06-25 2023-10-17 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3645741A4 (en) * 2017-06-25 2021-08-25 Systimmune, Inc. ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING
US20260008861A9 (en) * 2017-06-25 2026-01-08 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン, インク. 抗pd-l1抗体とその作製及び使用方法
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CA3171363A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
CA3173980A1 (en) * 2020-03-03 2021-09-10 Systimmune, Inc. Anti-cd19 antibodies and methods of using and making thereof
TWI908779B (zh) * 2020-03-17 2025-12-21 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
BR112023005152A2 (pt) * 2020-09-21 2023-04-25 Systimmune Inc Anticorpo biespecífico com especificidade intensificada (seba)
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
US20240262930A1 (en) * 2021-05-28 2024-08-08 Xyone Therapeutics Inc. Multi-specific antibody constructs against the muc1-c/extracellular domain (muc1-c/ed)
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
CN118974091A (zh) * 2022-04-11 2024-11-15 阿斯利康(瑞典)有限公司 T细胞结合蛋白
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354600A1 (en) * 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
MX386342B (es) * 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN107531784B (zh) 2015-04-29 2021-08-27 生物医学研究所 通过多特异性抗体超强力地中和细胞因子和其用途
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
ES3056995T3 (en) * 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201808457PA (en) * 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106589129B (zh) 2016-12-30 2021-03-05 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
US11787863B2 (en) * 2017-06-25 2023-10-17 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Similar Documents

Publication Publication Date Title
JP2020529864A5 (cg-RX-API-DMAC7.html)
JP2022510218A5 (cg-RX-API-DMAC7.html)
Weidle et al. Tumor-antigen–binding bispecific antibodies for cancer treatment
AU2015303135B2 (en) SIRP-alpha immunoglobulin fusion proteins
ES2850325T3 (es) Anticuerpos biespecíficos contra CD3epsilon y ROR1
JP2020530777A5 (cg-RX-API-DMAC7.html)
JP2020530306A5 (cg-RX-API-DMAC7.html)
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2018525033A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
Urbanska et al. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
JP2022551081A5 (cg-RX-API-DMAC7.html)
JP2023502108A5 (cg-RX-API-DMAC7.html)
JP2024508672A5 (cg-RX-API-DMAC7.html)
CN115066274A (zh) 三价结合分子
EP4355781A1 (en) Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases
CN115698088A (zh) 免疫细胞衔接器多特异性结合蛋白及其制备和应用
AU2017359813A1 (en) Anti-PD-1/anti-HER2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
JP2020535796A5 (cg-RX-API-DMAC7.html)
CN111699201A (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
JP2023546725A5 (cg-RX-API-DMAC7.html)
JP2022513372A5 (cg-RX-API-DMAC7.html)
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
CN113490690A (zh) 异源二聚体融合蛋白